We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Neurocrine (NBIX) Could Be Positioned for a Surge
Read MoreHide Full Article
Neurocrine Biosciences, Inc. (NBIX - Free Report) is a discoverer and developer of pharmaceuticals for neurological and endocrine-related disorders and diseases that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NBIX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Neurocrine could be a solid choice for investors.
Current Quarter Estimates for NBIX
In the past 30 days, seven estimates have gone higher for Neurocrine while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 40 cents a share 30 days ago, to 67 cents today, a move of 67.5%.
Current Year Estimates for NBIX
Meanwhile, Neurocrine’s current year figures are also looking quite promising, with 12 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, moving from a loss of 31 cents per share 30 days ago to earnings of 80 cents per share today, a significant increase.
The stock has also started to move higher lately, adding 8.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Why Neurocrine (NBIX) Could Be Positioned for a Surge
Neurocrine Biosciences, Inc. (NBIX - Free Report) is a discoverer and developer of pharmaceuticals for neurological and endocrine-related disorders and diseases that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NBIX’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Neurocrine could be a solid choice for investors.
Current Quarter Estimates for NBIX
In the past 30 days, seven estimates have gone higher for Neurocrine while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 40 cents a share 30 days ago, to 67 cents today, a move of 67.5%.
Current Year Estimates for NBIX
Meanwhile, Neurocrine’s current year figures are also looking quite promising, with 12 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, moving from a loss of 31 cents per share 30 days ago to earnings of 80 cents per share today, a significant increase.
Neurocrine Biosciences, Inc. Price and Consensus
Neurocrine Biosciences, Inc. price-consensus-chart | Neurocrine Biosciences, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 8.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>